Mineral trioxide aggregate as a pulpotomy medicament: A narrative review
- 192 Downloads
Background: Several medicaments have been used to devitalize remaining pulp or maintain pulp vitality and promote healing. Based on pulpal biocompatibility and good sealing ability, a growing interest in more biocompatible materials promotes mineral trioxide aggregate (MTA) as an alternative to traditional medicaments. Uniquely, MTA can preserve pulpal health predictably and promote healing with pulp regeneration. Methods: Using electronic search all papers published since 1993 on the use of MTA in paediatric dentistry were identified. This paper provides a narrative review of the current literature on MTA, formocresol, ferric sulphate and calcium hydroxide with particular reference to primary teeth pulpotomy medication. Conclusion: The use of formocresol or formaldehyde-based medicaments should be replaced with more biocompatible medicaments possessing antimicrobial and pulpal regenerative properties. Of the four pulpotomy medicaments discussed, mineral trioxide aggregate is recommended as the medicament of choice.
Key wordsPulp therapy dental materials mineral trioxide aggregate formocresol ferric sulphate
Unable to display preview. Download preview PDF.
- American Academy of Pediatric Dentistry. Guideline on pulp therapy for primary and young permanent teeth. Pediatr Dent 2007-8;29 [Reference manual]:163–7.Google Scholar
- Australasian Academy of Paediatric Dentistry (Inc.). Guidelines for pulp therapy for primary and young permanent teeth. 1st ed. 2002;29–30.Google Scholar
- Cuisia ZE, Musselman R, Schneider P, Dumett CJR. A study of mineral trioxide aggregate pulpotomies in primary molars. Pediatr Dent 2001;23:168.Google Scholar
- Doyle WA, McDonald RE, Mitchell DF. Formocresol versus calcium hydroxide in pulpotomy. J Dent Child 1962;29:86–97.Google Scholar
- Gruythuysen RJ, Weerheijm KL. Calcium hydroxide pulpotomy with a light cured cavity sealing material after two years. J Dent Child 1997;64:251–3.Google Scholar
- International Agency for Research on Cancer. Press release no. 153, 15 June 2004. Available at: http://www.iarc.fr/ENG/Press_Releases/archives/pr153a.html Accessed 8 Aug 2007.
- Jabbarifar SE, Khademi DD, Ghasemi DD. Success rates of formocresol pulpotomy versus mineral trioxide aggregate in human primary molar tooth. J Res Med Sci 2004;6:55–8.Google Scholar
- Nadin G, Goel BR, Yeung CA, Glenny AM. Pulp treatment for extensive decay in primary teeth. Cochrane Database Syst Rev. 2003;1:CD0033220.Google Scholar
- Ng FK. An evidence-based assessment on the effectiveness of four primary molar pulpotomy medicaments [DClinDent thesis]. Victoria, Australia: The University of Melbourne; 2007.Google Scholar
- Ng FK, Messer LB. Mineral trioxide aggregate as a pulpotomy medicament: An evidence-based assessment. J Dent Res [IADR ANZ division 2007-Abstract 0.35].Google Scholar
- Ranly DM, Horn D. Assessment of systemic distribution and toxicity of formaldehyde following pulpotomy treatment: Part Two. J Dent Child 1987;54:40–4.Google Scholar
- Rocha M, Baroni R, Santos L, Girardi K. Ca(OH)2 and MTA pulpotomies in primary teeth: one year results. Int J Paediatr Dent 1999;9(Suppl 1):102 [Abstr P5.35].Google Scholar
- Schroder U, Granath LE. Early reaction of intact human teeth to calcium hydroxide following experimental pulpotomy and its significance to the development of hard tissue barrier. Odont Revy 1971;22:379–96.Google Scholar
- Schroder U. Effect of an extra-pulpal blood clot on healing following experimental pulpotomy and capping with calcium hydroxide. Odont Revy 1973;24:257–68.Google Scholar
- Spencer DL. Physical properties of a new mineral trioxide aggregate material. [M.Sc thesis]. Richmond, Virginia: Virginia Commonwealth University; 2004.Google Scholar
- Williams D. Revisiting the definition of biocompatibility. Med Device Technol 2003;14:10–3.Google Scholar